,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny breast04', 'breast', 'in person']
#asco2022 destiny breast04 stunning, practice changing data. clinically meaningful improvements in pfs and os in all analyses. os 23.4 mo vs 17.5 no in all patients. tears of joy, this will lead to more advances. lucky to be here in person
Med Director, Clinical researcher, Breast Cancer Oncologist @bonsecours. What do oncology and bourbon have in common? ME. Tweets my own, free ?? reviews; he/his